Zetamatrix, established in 2021, is gaining recognition as a pioneer in the Biotechnology and Manufacturing sectors. Headquartered in The Netherlands, this innovative start-up focuses on creating next-generation biomaterials, specifically formulating bioinks for 3D cell culture and bioprinting applications.
Zetamatrix's primary product is a line of hydrogels that serve as extracellular-matrix environments. These bioinks replicate the properties of specific tissues, facilitating realistic 3D environments where cells can grow and reproduce effectively. This breakthrough technology holds significant potential in advancing tissue engineering and regenerative medicine, paving the way for new solutions in healthcare.
Sustained by a $1.10M Seed Round investment received on 01 March 2021, Zetamatrix continues to develop its product offerings and expand its market reach. For venture capitalists interested in driving innovation and supporting transformative technologies, Zetamatrix represents a notable opportunity to influence the future of biomaterials.